Trial Profile
A Phase 2 Randomized, Open-Label, Multicenter Study Evaluating Administration of Repeated Intravitreal Doses of ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 17 Mar 2021
Price :
$35
*
At a glance
- Drugs HI-con1 (Primary) ; Aflibercept
- Indications Wet age-related macular degeneration
- Focus Proof of concept; Therapeutic Use
- Acronyms DECO
- Sponsors Iconic Therapeutics
- 19 Feb 2021 Status changed to discontinued.
- 24 Aug 2020 Status changed from active, no longer recruiting to completed.
- 07 Nov 2018 Status changed from recruiting to active, no longer recruiting.